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Introduction {#sec004}
============

In accordance with the Pharmacopoea Europaea, the standardized Ginkgo biloba extract (GBE, LI1370) consists of 22.0--27.0% ginkgo flavone glycosides as well as 5.4--6.6% terpenoids. GBE has been shown to improve effectively mitochondrial defects through several modes of action such as antioxidant and the radical scavenging properties as well as amelioration of mitochondrial respiration and adenosine triphosphate (ATP) production \[[@pone.0225761.ref001]--[@pone.0225761.ref004]\]. The flavonoids (including isohammetin and kaempferol) seem to play an important role for free radical scavenging, whereas terpene lactones show substantial mitochondria-protecting properties \[[@pone.0225761.ref005]\]. Terpenes (including bilobalide and ginkgolides A,B,C) prevent membrane damage against free radicals and possess also several other neuroprotective properties. Flavonoids can act via neuronal receptors and modulate transcription factors, kinase signalling pathways and protein expression related to learning process and memory as well as cell proliferation \[[@pone.0225761.ref006]\]. Previously, we have investigated the protective effects of the extract LI 1370 on energy metabolism defects in human neuroblastoma cells (SH-SY5Y cells) \[[@pone.0225761.ref007]\]. GBE treatment (24hr, 100 μg/ml) was able to increase the coupling state of mitochondria leading to an amelioration of the efficiency of the mitochondrial electron transport chain (ETC). The increase of mitochondrial bioenergetics through the oxygen consumption and ATP production is due to the modulation of mitochondrial complex I, III and IV activities. Moreover, GBE treatment induced also an increase in the mitochondrial DNA (mtDNA) content. Thus, we clearly highlighted in our previous report the beneficial effect of GBE on mitochondrial function and energy metabolism \[[@pone.0225761.ref007]\]. Mitochondria are central regulators of fundamental processes in neuroplasticity, including neurite outgrowth \[[@pone.0225761.ref008]\]. Neurite outgrowth is a process where forming neurons produce new projections as they grow in response to guidance cues. Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or neurotrophins, are examples of such stimuli that regulate neurite growth. Müller and colleagues already demonstrated preliminary evidence that the standardized Gingko biloba extract EGb761^®^ is able to increase the length of dendrites in a [cell line](https://en.wikipedia.org/wiki/Cell_culture#Common_cell_lines) derived from a [pheochromocytoma](https://en.wikipedia.org/wiki/Pheochromocytoma) of the [rat](https://en.wikipedia.org/wiki/Rat) [adrenal medulla](https://en.wikipedia.org/wiki/Adrenal_medulla) (PC12 cells) \[[@pone.0225761.ref009]\] but the underlying pathways of GBE effect on the neurite outgrowth are still unclear.

For this purpose, we first characterized the effect of GBE on neurite outgrowth in differentiated SH-SY5Y neuroblastoma cells using standard two-dimensional (2D) and three-dimensional (3D) cellular culture models. Then, we investigated the intracellular signal transduction pathways involved in promoting the neuroplasticity which is targeted by GBE. Overall, the data reported in the present study provide new insights into the molecular mechanisms of neurite extension induced by GBE, highlighting new potential therapeutic targets.

Material and methods {#sec005}
====================

Chemicals and reagents {#sec006}
----------------------

Dulbecco's-modified Eagle medium (DMEM), fetal calf serum (FCS), penicillin/streptomycin, neurobasal medium, and retionic acid were from Sigma-Aldrich (St. Louis, MO, USA). Glutamax and B27 supplement were from Gibco Invitrogen (Waltham, MA, USA). NGF was from Lubio (Zürich, Switzerland). Standardized Ginkgo biloba extract (GBE) LI 1370 (composition: 22.0--27.0% flavone glycoside content and 5.4--6.6% terpene lactone content, DEV 35--67: 1, extractant: acetone 60% (V / V)) was produced and supplied by Vifor SA, Villars-sur-Glâne, Switzerland.

Cell culture {#sec007}
------------

Human SH-SY5Y neuroblastoma cells were grown at 37°C in a humidified incubator chamber under an atmosphere of 7.5% CO~2~ in DMEM supplemented with 10% volume/volume (v/v) heat-inactivated FCS, 2 mM Glutamax and 1% (v/v) penicillin/streptomycin. Cells were passaged 1--2 times per week, and plated for treatment when they reached 80--90% confluence \[[@pone.0225761.ref010]\]. This cell line is a "neuron-like" cellular model that is widely used in Neuroscience to study neuronal differentiation.

For 2D cell culture, cell plates were coated with collagen type I (Rat tail BD Bioscience) at 0.05 mg/ml.

For the 3D cell culture system, a BD PuraMatrix Peptide Hydrogel (BD Catalog \#354250 packaged in one vial containing 1% solution (w/v) of purified synthetic peptide) was used. 5mg/ml of PuraMatrix (0.5%, 50 μl for a 96-well plate) were obtained by dilution in sterile dH~2~O and added to the surface of the well. Gelation was promoted by carefully and slowly adding medium to each well (100 μl for a 96-well plate). Plates were placed in an incubator for 60 minutes to complete the gelation of the PuraMatrix. The medium was changed twice over a period of 1 hour to equilibrate the growth environment to physiological pH. Cells were carefully added in each well at of concentration of 5000 cells/well.

Treatment paradigm {#sec008}
------------------

SH-SY5Y neuroblastoma cells were plated in 96 wells plates (black with clear bottom) that were coated for the 2D or 3D cell culture. The next day, cell differentiation was induced by adding fresh neurobasal medium containing 1% fetal bovine serum and 10 μM retinoic acid (RA) for 3 days. Then, cells were treated either with 50 ng/ml of NGF (positive control) or with GBE at three different concentrations: 10, 100 and 500 ug/ml (concentrations selected on the basis of \[[@pone.0225761.ref007]\]). After 3 days of treatment, cells were fixed with 2% paraformaldehyde. All media were exchanged every 2 days to ensure the availability of growth factors and GBE components in the culture.

Immunostaining {#sec009}
--------------

The protocol was used with 2D or 3D surface cultures of cells in plates. For 96-well black microplates with a clear bottom, it was possible to directly image the samples without transferring the gel to a glass slide. Immunolabeling of neurites was performed using an anti βIII-tubulin and Alexa Fluor 488-conjugated secondary antibody (fluorescence emission in the green wavelength).

Microscopy and analysis (software) {#sec010}
----------------------------------

Images were taken using an inverted confocal microscope (Leica Microsystems TCS SPE DMI4000) attached to an external light source for enhanced fluorescence imaging (Leica EL6000) with a 10x objective. Pinhole settings were chosen in such a way that axially all the cells were entirely present within the confocal volume. For the 2D culture method, one layer was taken. For the 3D culture method, z-stacks were generated (3--4 layers) to visualize the whole 3D network. The maximum intensity projection was then used for analysis that was performed using ImageJ (Neurophology plugin) software to evaluate parameters of neuroplasticity:

-   Soma count

-   Neurite count

-   Total neurite length

-   Difference (Δ, delta) of increase in neurite count under treatment

-   Number of branching points = attachment point

-   Number of contact points = endpoint

-   Extent of neurite branching = ratio of attachment point number to ending point number

Characterization of neuroplasticity pathways via targeted protein expression profiling {#sec011}
--------------------------------------------------------------------------------------

*Quantitative detection of each protein was performed using the Luminex technology*: The MILLIPLEX^®^ MAP Akt/mTOR Phosphoprotein 11-plex Magnetic Bead Kit was used to detect changes in phosphorylated GSK3β (Ser9), Akt (Ser473), PTEN (Ser380), IGF1R (Tyr1135/Tyr1136), TSC2 (Ser939), and mTOR (Ser2448) in cell lysates using the Luminex^®^ system. Of note, the total level of targeted proteins was also assessed after GBE treatment but no significant effect was detected (Akt/mTOR protein 11-plex Magnetic Bead Kit 96-well Plate). The detection assay is a rapid, convenient alternative to Western Blotting and immunoprecipitation procedures. Each kit has sufficient reagents for one 96-well plate assay. Luminex^®^ uses proprietary techniques to internally color-code microspheres with multiple fluorescent dyes. Through precise concentrations of these dyes, distinctly colored bead sets of 500 5.6 μm non-magnetic or 80 6.45 μm magnetic polystyrene microspheres can be created, each of which is coated with a specific capture antibody. After an analyte from a test sample is captured by the bead, a biotinylated detection antibody is introduced. The reaction mixture is then incubated with Streptavidin-PE conjugate, the reporter molecule, to complete the reaction on the surface of each microsphere. The microspheres are illuminated, and the internal dyes fluoresce, marking the microsphere set(s) used in a particular assay. A second illumination source excites PE, the fluorescent dye on the reporter molecule. Finally, high-speed digital-signal processors identify each individual microsphere and quantify the result of its bioassay based on fluorescent reporter signals.

*Immunoassay protocol for lysate samples*: 3 days after treatment with 100 μg/ml GBE, SH-SY5Y cell pellets were isolated and treated with lysis buffer (Millipore Corp., Billerica, USA) containing protease inhibitors. Cell debris was removed by centrifugation at 14 000 g for 15 min. Equal amounts of soluble protein lysates were analysed for the level of various phosphorylated proteins using MILLIPLEX MAP 11-plex Multi-Pathway Signalling Phosphoprotein kit on the Luminex 200 system (Millipore Corp.).

The multiplex assay was performed in a 96-well plate. The detailed procedure is as follows: the plate was wet with 50 μL assay buffer for 10 min and decanted. Then, the following solution was added: 25 μL beads, 25 μL assay buffer in blank wells, and 25 μL lysate at 0.8 mg/mL to sample or control wells. The plate was incubated O/N at 4°C. The beads were washed two times and 25 μL biotinylated detection Ab cocktail were added and the plate was incubated at RT for 1 hour. The beads were washed one time and 25 μL of streptavidin-phycoerythrin was added for a 15 min incubation at RT. 25 μL amplification buffer was added to the SAPE. SAPE/amplification buffer was removed and beads were suspended in 100 μL assay buffer. Plate reading was performed on Luminex instrumentation.

Statistical analysis {#sec012}
--------------------

Data are given as the mean ± SEM, normalized to the untreated control group (= 100%). Statistical analyses were performed using the Graph Pad Prism software. For statistical comparisons, one-way ANOVA was used, followed by Dunnett's multiple comparison tests versus the control (CTRL, untreated neuroblastoma cells). For statistical comparisons of two groups, Student unpaired *t*-test was used. P values \<0.05 were considered statistically significant.

Results {#sec013}
=======

GBE improved the neurite outgrowth in 2D cell culture {#sec014}
-----------------------------------------------------

To investigate the effect of GBE on neurite outgrowth, three different concentrations of GBE 10, 100 and 500 μg/ml were tested (based on our previous study \[[@pone.0225761.ref007]\]) on differentiated SH-SY5Y cells using the 2D cell culture method. Nerve Growth Factor (NGF, 50 pg/ml) which is known as promotor of cell growth and survival was used as positive control. The 2D pictures (one layer of cells) were taken with the confocal microscope and analysed with the ImageJ Neurophology software. After 3 days of treatment with GBE, the 100 μg/ml dose was the most efficient concentration to increase the neurite count to a similar extent than the NGF itself (about 77% increase when compared to the untreated cells (CTRL)) (Figs [1](#pone.0225761.g001){ref-type="fig"} and [2](#pone.0225761.g002){ref-type="fig"}). In fact, after 3 days, the treatment with GBE at 10 μg/ml ameliorated the total neurite length (about 52% of increase), attachment point (up to 113% of increase) as well as the endpoint with 71% of improvements when compared to untreated SH-SY5Y cells ([Fig 2](#pone.0225761.g002){ref-type="fig"}). However, at the higher concentration of 100 μg/ml, GBE significantly ameliorated all the parameters with an increase going up to 216% for the neurite outgrowth with a similar effect than the positive control NGF (Figs [1](#pone.0225761.g001){ref-type="fig"} and [2](#pone.0225761.g002){ref-type="fig"}) when compared to the untreated group. The higher concentration 500 μg/ml of GBE showed no significant effect on the neurite outgrowth in this model ([Fig 2](#pone.0225761.g002){ref-type="fig"}).

![GBE increased the neurite outgrowth of neuroblastoma cells after 3 days of treatment in a 2D cell culture.\
Pictures were taken using a confocal microscope (x10). Immunostaining (IMS) with βIII- tubuline/Alexa488: pictures display neurite extension between the cells (upper panels; [S1 Fig](#pone.0225761.s001){ref-type="supplementary-material"}). Quantification of the neurite outgrowth parameters such as the attachment points (middle panels) and the endpoint numbers (lower panels), after NGF or GBE treatment are shown (Blue: soma, red: neurite, green point: attachment point, yellow point: endpoint).](pone.0225761.g001){#pone.0225761.g001}

![GBE increased the neurite outgrowth of neuroblastoma cells after 3 days of treatment in a 2D cell culture.\
Quantification of [Fig 1](#pone.0225761.g001){ref-type="fig"} using NeurophologyJ ([S1 Table](#pone.0225761.s003){ref-type="supplementary-material"}). At 100 μg/ml GBE significantly increased: (A) cell number (soma count), (B) number of neurites (neurite count), (C) neurite length, (D) number of attachment points, (E) number of endpoints, and (F) extent of neurite branching. The effect of GBE was similar than the positive control NGF when compared to the untreated cells. The red line represents the effects of NGF-treated cells. Values represent the mean ±SEM of three independent experiments and were normalized to 100% of untreated CTRL cells. One way ANOVA and post hoc Dunnett's multiple comparisons versus untreated neuroblastoma cells (CTRL) \*P\<0.05,\*\*P\<0.01,\*\*\*P\<0.001.](pone.0225761.g002){#pone.0225761.g002}

GBE increased the neurite extension of cells in 3D-matrix {#sec015}
---------------------------------------------------------

Based on the results obtained in the 2D cell culture system, we additionally evaluated the effect of the most effective concentration of GBE (100 μg/ml) using a 3D-Matrix system ([Fig 3](#pone.0225761.g003){ref-type="fig"}). In fact, we confirmed that GBE treatment (100 μg/ml) for 3 days ameliorated significantly neurite count (+79%), total neurite length (+75%), attachment (+138%) and endpoints (+64%) parameters and showed a positive trend to increase soma count and the extent of neurite branching compared to the untreated SH-SY5Y cells (Figs [3](#pone.0225761.g003){ref-type="fig"} and [4](#pone.0225761.g004){ref-type="fig"}). Pictures obtained with the z-stack projection of 3--4 layers of cells on 3D-matrix show a 3D view of neurite outgrowth of the SH-SY5Y cells allowing the visualization of the formation of neurites and their projections between the cells ([Fig 3](#pone.0225761.g003){ref-type="fig"}).

![GBE (100 μg/ml) induced neurite extension in a 3D-matrix by increasing the neurite outgrowth of neuroblastoma cells after 3 days of treatment.\
Pictures were obtained by merging 3--4 layers of cells (z-stack projection) on 3D-matrix using a confocal microscope (x10). Immunostaining (IMS) with βIII- tubuline/Alexa488: pictures display neurite extension between the cells (upper panels, [S2 Fig](#pone.0225761.s002){ref-type="supplementary-material"}). Quantification of the neurite outgrowth parameters such as the attachment points (middle panels) and the endpoint numbers (lower panels), after NGF or GBE treatment are shown (Blue: soma, red: neurite, green point: attachment point, yellow point: endpoint).](pone.0225761.g003){#pone.0225761.g003}

![GBE (100 μg/ml) increased the neurite outgrowth of neuroblastoma cells after 3 days of treatment using a 3D gel.\
Quantification of [Fig 3](#pone.0225761.g003){ref-type="fig"} using NeurophologyJ ([S2 Table](#pone.0225761.s004){ref-type="supplementary-material"}). GBE (100 μg/ml) ameliorated: (A) cell number (soma count), (B) number of neurites (neurite count), (C) neurite length, (D) number of attachment points, (E) number of endpoints, and (F) extent of neurite branching. The effect of GBE was similar than the positive control NGF when compared to the untreated cells. The red line represents the effects of NGF-treated cells. Values represent the mean ±SEM of three independent experiments and were normalized to 100% of untreated CTRL cells. One way ANOVA and post hoc Dunnett's multiple comparisons versus untreated neuroblastoma cells (CTRL) \*P\<0.05. Student t-test ^+^P\<0.05,^++^P\<0.01.](pone.0225761.g004){#pone.0225761.g004}

Targeted protein expression profiling induced by GBE treatment {#sec016}
--------------------------------------------------------------

Previous reports showed that GBE enhanced BDNF expression *in vitro* and *in vivo* \[[@pone.0225761.ref007], [@pone.0225761.ref011]--[@pone.0225761.ref013]\]. Because BDNF plays a role in neuroplasticity and neurite outgrowth, we decided to assess whether GBE was able to influence the BDNF signaling cascade by focusing on the Akt/mTOR pathway.

The Akt/mTOR signaling pathway is regulated by posttranslational modifications such as protein phosphorylation at multiple distinct sites, which are indicative of the activity state of the target protein. To characterize the effect of GBE (100 μg/ml, 3 days of treatment) on this pathway, quantitative detection of several proteins using Luminex technology kit was conducted ([Fig 5](#pone.0225761.g005){ref-type="fig"}). The MILLIPLEX^®^ MAP Akt/mTOR phosphoprotein multiplex magnetic bead kit was used to detect changes in specific phosphorylated proteins in cell lysates. Compared to untreated cells, GBE (100 μg/ml) was able to increase significantly the level of the phosphoproteins Akt (Ser473), GSK3β (Ser9), IGF1R (Tyr1135/Tyr1136), mTOR (Ser2448), TSC2 (Ser939) and PTEN (Ser380) (Figs [5](#pone.0225761.g005){ref-type="fig"} and [6](#pone.0225761.g006){ref-type="fig"}).

![Activation of the Akt/mTOR signaling pathway after GBE (100 μg/ml) treatment in neuroblastoma cells.\
Neuroblastoma cells (SH-SY5Y) stimulated with GBE (100 μg/ml) (3 days) were lysed in MILLIPLEX^®^ MAP lysis buffer containing protease inhibitors. 20 μg total protein of each lysates diluted in MILLIPLEX^®^ MAP assay buffer 2 were analyzed according the assay protocol (lysate incubation at 4°C overnight). The Median Fluorescence Intensity (MFI) was measured measurements for the phosphoproteins Akt (Ser473), GSK3β (Ser9), IGF1R (Tyr1135/Tyr1136), mTOR (Ser2448), TSC2 (Ser939) and PTEN (Ser380) with the Luminex^®^ system ([S3 Table](#pone.0225761.s005){ref-type="supplementary-material"}). The figure represents the average and standard deviation of three replicates. Student t-test \*P\<0.05, \*\*\*P\<0.001.](pone.0225761.g005){#pone.0225761.g005}

![Possible pathways involved in GBE-induced neuroplasticity pathway.\
We propose that neuroprotective effects of GBE are mediated via multiple pathways. In the present study, we show that GBE increases IGF1R phosphorylation (Tyr1135/Tyr1136), which activates the Akt/mTOR pathway. Activation of Akt by phosphorylation (Ser473) inhibits TSC2 (phosphorylation at Ser939) which activates mTOR (phosphorylation at Ser2448) and induces neuronal survival, neurite outgrowth and neuroplasticity. In parallel, GBE inactivates the antagonizing pathways by increasing the phosphorylation of PTEN and GSK3β (at Ser380 and Ser9 respectively). Of note, the growth factors NGF and BDNF activate also the Akt/mTOR pathway, suggesting that GBE may also act via these growth factors to induce its neuroprotective effects. Besides, our previous study showed that GBE increases mitochondrial bioenergetics and decreases reactive oxygen species production (Rhein et al., PlosONE 2009), which may also play a role in neuroprotection and neurite outgrowth. Akt is also known as protein kinase B (PKB). IGF-1R, insulin-like growth factor-1; PI3K, phosphoinositide 3-kinase; PIP2 or PIP3, phosphatidylinositol triphosphate; PTEN, phosphatase and tensin homolog; GSK3, glycogen synthase kinase 3; TSC, tuberous sclerosis protein; mTOR, mammalian target of rapamycin.](pone.0225761.g006){#pone.0225761.g006}

Thus, GBE seems to activate the Akt/mTOR pathway that supports cell survival and neurite outgrowth.

Discussion {#sec017}
==========

In this report, we demonstrated that the standardized GBE LI 1370 induced a significant increase of the neurite outgrowth in neuroblastoma cells after 3 days of incubation at 10 μg/ml and 100 μg/ml. These effects were comparable with the positive control NGF (50 ng/ml). In line, another standardized GBE EGb761^®^, enhanced neuritic outgrowth of PC12 cells at the same dose of 100μg/ml \[[@pone.0225761.ref009]\]. Among the three major constituents (ginkgolide, bilobalide, flavonoids), flavonoids seemed to be the most active group \[[@pone.0225761.ref009]\]. Moreover, Wang and Han showed that neurite outgrowth is also dramatically increased upon GBE treatment (50 μg/ml) in neural stem cells (NSCs) \[[@pone.0225761.ref014]\]. Besides, GBE treatment (50 μg/ml) significantly enhanced the formation and growth of neurosphere \[[@pone.0225761.ref014]\].

GBE-induced neurite outgrowth was compared in 3D-matrix of SH-SY5Y cultures using Puramatrix peptide hydrogel and in a standard 2D SH-SY5Y culture model using collagen I. In 3D culture, GBE (3 days, 100 μg/ml) showed even a better effect on neurite extension compared to the 2D SH-SY5Y culture.

NGF plays a crucial role in differentiation, survival and the stimulation of neurite outgrowth in neuronal cells \[[@pone.0225761.ref015]\]. The neurotrophic factor NGF has therefore been considered for treating the neurodegenerative diseases such as AD \[[@pone.0225761.ref016]--[@pone.0225761.ref019]\]. Neuroplasticity, the capacity of synapses to undergo structural adaptations in response to functional need or dysfunctions is deteriorated in aging and Alzheimer's disease \[[@pone.0225761.ref020]\]. Isorhamnetin, an aglycon of the flavonoids from *Ginkgo biloba* plant, was shown to be an inducer of neuroplasticity by increasing on the neurite length of the PC12 cells \[[@pone.0225761.ref009], [@pone.0225761.ref021]\]. Isorhamnetin was shown to induce a significant enhancement of neurotrophin (such as NGF)-mediated neurite outgrowth in PC12 cells \[[@pone.0225761.ref022]\]. Isorhamnetin effectively upregulated the production and release of NGF, BDNF and glial cell line-derived neurotrophic factor (GDNF) in primary rat astrocytes through estrogen signaling pathways \[[@pone.0225761.ref023]\]. Studies conducted using the standardized Gingko biloba extract (EGb761) showed that this extract enhances phosphorylation of cyclic-AMP Response Element Binding Protein (CREB) and increases the levels of phosphoCREB and BDNF, a member of the neurotrophin family of growth factors that plays a role in the proliferation, differentiation, and growth of neurons during development \[[@pone.0225761.ref012], [@pone.0225761.ref024], [@pone.0225761.ref025]\]. However, in N2a cells, a murine neuroblastoma cell line, the increased phosphorylation of CREB by GBE was not dependent on the PKA signalling pathway, a direct upstream regulator of CREB \[[@pone.0225761.ref012]\]. Furthermore, GBE reduced the hyperphosphorylation of tau at Ser262, Ser404, Ser396 and Thr231 sites as well as rescued the activity of tau kinase (GSK3β) in a rat model of AD \[[@pone.0225761.ref026]\]. Thus, the neuroprotective mechanism(s) of GBE could be mediated via multiple pathways such as by an indirect effect via inhibiting glycogen synthase kinase 3 (GSK3) involved in the PI3K/AKT/mTOR pathway that is related to neurogenesis, proliferation and migration \[[@pone.0225761.ref027], [@pone.0225761.ref028]\]. As we demonstrated, the Akt/mTOR signalling pathway also seems to play an important role in the effect of GBE on neurite outgrowth of human neuroblastoma cells (SH-SY5Y cells). [Fig 6](#pone.0225761.g006){ref-type="fig"} summarizes the effects of GBE on this specific pathway. GBE induced phosphorylation of IGF-1R receptor (Tyr1135/Tyr1136) which invokes downstream changes in the metabolic pathway ([Fig 6](#pone.0225761.g006){ref-type="fig"}) \[[@pone.0225761.ref029]\]. This may trigger a signaling transduction cascade to the cell nucleus thus modulating some cellular functions such as promotion of cell survival via PI3K/Akt ([Fig 6](#pone.0225761.g006){ref-type="fig"}) \[[@pone.0225761.ref029]\]. These act in a coordinated manner to regulate lipid, glucose, and protein metabolism. PIP3 is produced by PI3K-dependent phosphorylation of PIP2, which in turn activates Akt and mammalian target of rapamycin (mTOR) \[[@pone.0225761.ref030]\]. The reverse and antagonizing reaction is regulated by the phosphatase PTEN (phosphatase and tensin homolog) \[[@pone.0225761.ref031], [@pone.0225761.ref032]\]. In the nervous system, PTEN inhibition leads to stem cell proliferation, neurite outgrowth and dendritic spine maturation \[[@pone.0225761.ref030], [@pone.0225761.ref033]\].

Notably, we could show that GBE was able to increase the inactivation of PTEN (phosphorylation at Ser380) which activates Akt (phosphorylation at Ser473) and mTOR (phosphorylation at Ser2448). In parallel, GBE inhibited signaling molecules like GSK3 \[[@pone.0225761.ref030]\]. Indeed, the activated form of Akt influences protein synthesis via mTOR as well as glucose metabolism via GSK3. We detected an increase of phosphorylated GSK3β (at Ser9), which is known to play a central role in numerous cellular processes, including metabolism, cell-cycle and survival ([Fig 6](#pone.0225761.g006){ref-type="fig"}).

Akt activates the mTOR pathway via phosphorylation of tuberous sclerosis protein 2 (TSC2). GBE was able to increase the inactive form of TSC2 at the ser939 site as well as the active form of mTOR ([Fig 6](#pone.0225761.g006){ref-type="fig"}) \[[@pone.0225761.ref034]\]. These findings suggest that GBE might promote neurite growth via the PI3K/AKT/mTOR signaling pathway that potentially modulates neuronal plasticity. Therefore and in line with previous reports \[[@pone.0225761.ref012], [@pone.0225761.ref013]\], we propose that GBE is able to increase neurotrophic factors like BDNF, which also seems to be able to trigger the cascade activating the PI3K/AKT/mTOR signaling pathway and inhibiting PTEN and GSK3β ([Fig 6](#pone.0225761.g006){ref-type="fig"}). Further experiments are needed to dissect the exact underlying mechanisms correlating neurite outgrowth and the activation of AKT/mTOR signaling, for example by using an inhibitor of AKT (e.g. MK2206), and to detect the potential changes in the respective downstream signals \[[@pone.0225761.ref035]\]. Together with the protective effects of GBE on mitochondrial function \[[@pone.0225761.ref007]\], this might lead to neuronal survival, neuroplasticity and neurite outgrowth.

In conclusion, the present study demonstrates that GBE can markedly promote neurite outgrowth and activates the phosphorylation of Akt, GSK3β, IGF1R, mTOR, TSC2 and PTEN. In line with the already-mentioned mitochondrial function improving properties of GBE, it might represent one possible important pathway contributing to the initiation of neurite protrusion and subsequent elongation.

Supporting information {#sec018}
======================

###### Original pictures (confocal microscope, x10, immunostaining (IMS) with βIIItubuline/ Alexa488) of a 2D cell culture used for analysis using ImageJ software (Figs [1](#pone.0225761.g001){ref-type="fig"} and [2](#pone.0225761.g002){ref-type="fig"}).

(TIF)

###### 

Click here for additional data file.

###### Original pictures (confocal microscope, x10, immunostaining (IMS) with βIIItubuline/ Alexa488) of a 3D-matrix cell culture used for analysis using ImageJ software (Figs [3](#pone.0225761.g003){ref-type="fig"} and [4](#pone.0225761.g004){ref-type="fig"}).

(TIF)

###### 

Click here for additional data file.

###### The data are presented as mean (M), standard deviation (±SD) corresponding to the number of cells (N).

Values are normalized on 100% of the control group (untreated CTRL, N = 108).

(TIF)

###### 

Click here for additional data file.

###### The data are presented as mean (M), standard deviation (±SD) corresponding to the number of cells (N).

Values are normalized on 100% of the control group (untreated CTRL, N = 112).

(TIF)

###### 

Click here for additional data file.

###### The Median Fluorescence Intensity (MFI) values are presented as mean (M), standard deviation (±SD) and number of replicates (n).

(TIF)

###### 

Click here for additional data file.
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In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.\"

3.  Thank you for stating the following in the Financial Disclosure section:

This study was supported by a principal investigator- initiated research grant supported by Vifor SA, Switzerland.

We note that you received funding from a commercial source: Vifor SA, Switzerland.

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other [relevant declarations](http://www.plosone.org/static/competing.action) relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript by Anne Eckert and colleagues investigate the effect of the Standardized Ginkgo biloba extract (GBE) LI1370 on neuroplasticity and neurite outgrowth using SH-SY5Y neuroblastoma cells in a 2D and 3D surface culture. The authors evaluated parameters of neurite outgrowth and showed that GBE (10 and 100 µg/ml) significantly increased neurite outgrowth after 3 days of treatment with a comparable effect than that NGF. The investigators also showed an increase of phosphorylated IGF1R (Tyr1135/Tyr1136), Akt (Ser473), TSC2 (Ser939), mTOR (Ser2448), PTEN (Ser380) and GSK3β (Ser9) after the treatment of GBE.

Although the role of GBE in promoting dendritic growth has been confirmed by others, the mechanism is not clear and it's attractive to explore the underlying pathways of GBE effect on the neurite outgrowth. The Luminex technology used in this manuscript is interesting, which could quantitatively detect each protein. I may have missed something important, and I was confused how the investigators drawn the conclusion that GBE promotes neurite growth via activation of the PI3K/Akt/mTOR pathway. It may be appropriate to Inhibit or enhance a site in the pathway and detect changes in downstream signals.

Minor comments:

1\. Please add a citation for this sentence "By generating energy, regulating subcellular calcium and redox homeostasis, mitochondria play an important role in controlling fundamental processes in neuroplasticity, including neural differentiation, neurite outgrowth, neurotransmitter release and dendritic remodeling".

2\. Please confirm whether reference 9, 10 and 24 were incorrectly cited.

3\. Please confirm reference 27 has been cited at corresponding location in this manuscript.

Reviewer \#2: The study is intended to investigate the intracellular signal transduction pathways involved in promoting the neuroplasticity which is targeted by GBE. The topic is a hot spot at present.

See attached file for minor linguistic errors

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

###### 

Submitted filename: v1_MANUSCRIPT lejri et al.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0225761.r002

Author response to Decision Letter 0

10 Oct 2019

Dear editors and dear reviewers,

Thank you very much for the time you took to read and review our manuscript as well as for your valuable comments which motivated us to improve our work. We are grateful for your advice and we revised our manuscript accordingly. We tried to address your comments in the best way. You can see all the changes throughout the manuscript marked in green. We changed one by one all of the requested modifications that were suggested by the reviewer 1 and we corrected the linguistic errors identified by the reviewer 2. We also adapted the title in accordance to the involvement of the Akt/ mTOR pathway discussed in the manuscript.

Especially, we modified the following:

JOURNAL REQUIREMENTS:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf>

<http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response: We re-organized the manuscript according to the journal PLOS ONE\'s style requirements including title, author, affiliations and the manuscript body formatting guidelines. We shorted the corresponding author section with only the email as required. We modified also the figure citations in the whole manuscript (pages 10 and 11, 16 and 17).

2\. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:

<https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0029-1240204>

<https://www.sciencedirect.com/science/article/pii/S0149763414000256?via%3Dihub>

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.\"

Response: We completely agree with the editors. We added some references from our own work (page 3 and 5). The section (pages 3) was shortened and rephrased.

3\. Thank you for stating the following in the Financial Disclosure section:

This study was supported by a principal investigator- initiated research grant supported by Vifor SA, Switzerland.

We note that you received funding from a commercial source: Vifor SA, Switzerland.

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Response: The study was only partially supported by Vifor SA, Switzerland. To avoid any misunderstanding, the acknowledgement was removed from the manuscript.

Please now state:

Financial disclosure: This study was partly supported by a principal investigator (AE) - initiated research grant supported by Vifor Pharma Switzerland, with regard to consumables and materials as well as GBE supply. Remaining funding was provided by grants from the Swiss National Science Foundation (SNF \#31003A_149728, to AE) and Synapsis Foundation - Alzheimer Research Switzerland ARS to AG, and funding from the Transfaculty Research Platform, Molecular & Cognitive Neuroscience, University of Basel. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests Statement: The authors have read the journal's policy and have the following conflicts: AE received study grants from Vifor Pharma Switzerland. Moreover AE and AG received lecturer/consultant fees from Vifor Pharma Switzerland. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

REVIEWER 1:

This manuscript by Anne Eckert and colleagues investigate the effect of the Standardized Ginkgo biloba extract (GBE) LI1370 on neuroplasticity and neurite outgrowth using SH-SY5Y neuroblastoma cells in a 2D and 3D surface culture. The authors evaluated parameters of neurite outgrowth and showed that GBE (10 and 100 µg/ml) significantly increased neurite outgrowth after 3 days of treatment with a comparable effect than that NGF. The investigators also showed an increase of phosphorylated IGF1R (Tyr1135/Tyr1136), Akt (Ser473), TSC2 (Ser939), mTOR (Ser2448), PTEN (Ser380) and GSK3β (Ser9) after the treatment of GBE.

Although the role of GBE in promoting dendritic growth has been confirmed by others, the mechanism is not clear and it's attractive to explore the underlying pathways of GBE effect on the neurite outgrowth. The Luminex technology used in this manuscript is interesting, which could quantitatively detect each protein. I may have missed something important, and I was confused how the investigators drawn the conclusion that GBE promotes neurite growth via activation of the PI3K/Akt/mTOR pathway. It may be appropriate to Inhibit or enhance a site in the pathway and detect changes in downstream signals.

Response: We thank the reviewer 1 for this valuable comment. We thoroughly state in the revised manuscript version that the effect of GBE on neurite outgrowth possibly involves the activation of the PI3K/Akt/mTOR pathway (Pages 13 to 15). We demonstrated in our manuscript that GBE is able to improve the neurite outgrowth and to increase the phosphorylated protein involved the PI3K/Akt/mTOR pathway. We state that the PI3K/Akt/mTOR signaling pathway seems to play an important role in the effects of GBE on neurite outgrowth (pages 13 and page 14), and that the activation of this pathway may represent one possible mechanism.

In addition, we completely agree with the reviewer 1 that further experiments are needed to dissect the exact underlying mechanisms correlating neurite outgrowth with the activation of PI3K/Akt/mTOR pathway, by using "as suggested by the reviewer", specific inhibitors, e.g: AKT inhibitor, MK2206 (Yu et al 2018 PMID: 30098550) to see if a treatment with GBE still induces the expansion of the neurite as well as activates the respective downstream signal (page 14).

Again, we thank the reviewer for this suggestion that we keep in mind for our further investigations. Accordingly, the section (pages 13 to 15) and the title were modified.

Modified title: Ginkgo biloba extract increases neurite outgrowth and activates the Akt/mTOR pathway

Minor comments:

1\. Please add a citation for this sentence "By generating energy, regulating subcellular calcium and redox homeostasis, mitochondria play an important role in controlling fundamental processes in neuroplasticity, including neural differentiation, neurite outgrowth, neurotransmitter release and dendritic remodeling".

Response: You are right, thank you. The sentence (page 3) was rephrased and the corresponding reference was added (Cheng et al 2010, PMID: 20957078)

2\. Please confirm whether reference 9, 10 and 24 were incorrectly cited.

Response: We apologize for these errors and we confirm that the references 9, 10 and 24 were incorrectly cited (pages 12 and 14). We corrected and replaced with the right citation respectively (pages 12 and 14).

3\. Please confirm reference 27 has been cited at corresponding location in this manuscript.

Response: Thank you for noticing our omission. We added the reference 27 (Cunha et al PMID: 20162032) at the corresponding location page 11 of our manuscript.

REVIEWER 2:

The study is intended to investigate the intracellular signal transduction pathways involved in promoting the neuroplasticity which is targeted by GBE. The topic is a hot spot at present.

See attached file for minor linguistic errors.

Response: We thank the reviewer 2 for this concern and for his/her corrections. We included his/her modifications about the general grammar and language improvement in the revised manuscript.

We thank the reviewers for their constructive criticism and most helpful comments that definitively helped to improve our manuscript. We hope that with the changes made, the manuscript is now suitable for publication.

###### 

Submitted filename: Response to reviewers_10.10.19.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0225761.r003

Decision Letter 1

Hu

Wenhui

Academic Editor

© 2019 Wenhui Hu

2019

Wenhui Hu

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

13 Nov 2019

Ginkgo biloba extract increases neurite outgrowth and activates the Akt/mTOR pathway

PONE-D-19-18727R1

Dear Dr. ECKERT,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Wenhui Hu, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The present study demonstrated that GBE could markedly promote neurite outgrowth and activited the phosphorylation of Akt, GSK3β, IGF1R, mTOR,TSC2 and PTEN，which might represent one possible important pathway. I am glad the authors have adopted my recommendations and modified the corresponding revisions to make the manuscript more rigorous.

Reviewer \#2: The authors carefully addressed all raised points by reviewers

Therefore, No further comments

It\'s now worthy of publication

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

10.1371/journal.pone.0225761.r004
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18 Nov 2019

PONE-D-19-18727R1

Ginkgo biloba extract increases neurite outgrowth and activates the Akt/mTOR pathway

Dear Dr. ECKERT:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Wenhui Hu

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**AE received study grants from Vifor Pharma Switzerland. Moreover AE and AG received lecturer/consultant fees from Vifor Pharma Switzerland. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
